Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Mar 15;3(3):CD011557.
doi: 10.1002/14651858.CD011557.pub2.

Interventions for preventing thrombosis in solid organ transplant recipients

Vignesh Surianarayanan  1 , Thomas J Hoather  2 , Samuel J Tingle  3 , Emily R Thompson  4 , John Hanley  5 , Colin H Wilson  4
Affiliations
Meta-Analysis

Interventions for preventing thrombosis in solid organ transplant recipients

Vignesh Surianarayanan et al. Cochrane Database Syst Rev. .

Abstract

Background: Graft thrombosis is a well-recognised complication of solid organ transplantation and is one of the leading causes of graft failure. Currently there are no standardised protocols for thromboprophylaxis. Many transplant units use unfractionated heparin (UFH) and fractionated heparins (low molecular weight heparin; LMWH) as prophylaxis for thrombosis. Antiplatelet agents such as aspirin are routinely used as prophylaxis of other thrombotic conditions and may have a role in preventing graft thrombosis. However, any pharmacological thromboprophylaxis comes with the theoretical risk of increasing the risk of major blood loss following transplant. This review looks at benefits and harms of thromboprophylaxis in patients undergoing solid organ transplantation.

Objectives: To assess the benefits and harms of instituting thromboprophylaxis to patients undergoing solid organ transplantation.

Search methods: We searched the Cochrane Kidney and Transplant Register of Studies up to 10 November 2020 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.

Selection criteria: We included all randomised controlled trials (RCTs) and quasi-RCTs designed to examine interventions to prevent thrombosis in solid organ transplant recipients. All donor types were included (donor after circulatory (DCD) and brainstem death (DBD) and live transplantation). There was no upper age limit for recipients in our search.

Data collection and analysis: The results of the literature search were screened and data collected by two independent authors. Dichotomous outcome results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Random effects models were used for data analysis. Risk of bias was independently assessed by two authors using the risk of bias assessment tool. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

Main results: We identified nine studies (712 participants). Seven studies (544 participants) included kidney transplant recipients, and studies included liver transplant recipients. We did not identify any study enrolling heart, lung, pancreas, bowel, or any other solid organ transplant recipient. Selection bias was high or unclear in eight of the nine studies; five studies were at high risk of bias for performance and/or detection bias; while attrition and reporting biases were in general low or unclear. Three studies (180 participants) primarily investigated heparinisation in kidney transplantation. Only two studies reported on graft vessel thrombosis in kidney transplantation (144 participants). These small studies were at high risk of bias in several domains and reported only two graft thromboses between them; it therefore remains unclear whether heparin decreases the risk of early graft thrombosis or non-graft thrombosis (very low certainty). UFH may make little or no difference versus placebo to the rate of major bleeding events in kidney transplantation (3 studies, 155 participants: RR 2.92, 95% CI 0.89 to 9.56; I² = 0%; low certainty evidence). Sensitivity analysis using a fixed-effect model suggested that UFH may increase the risk of haemorrhagic events compared to placebo (RR 3.33, 95% CI 1.04 to 10.67, P = 0.04). Compared to control, any heparin (including LMWH) may make little or no difference to the number of major bleeding events (3 studies, 180 participants: RR 2.70, 95% CI 0.89 to 8.19; I² = 0%; low certainty evidence) and had an unclear effect on risk of readmission to intensive care (3 studies, 180 participants: RR 0.68, 95% CI 0.12 to 3.90, I² = 45%; very low certainty evidence). The effect of heparin on our other outcomes (including death, patient and graft survival, transfusion requirements) remains unclear (very low certainty evidence). Three studies (144 participants) investigated antiplatelet interventions in kidney transplantation: aspirin versus dipyridamole (1), and Lipo-PGE1 plus low-dose heparin to "control" in patients who had a diagnosis of acute rejection (2). None of these reported on early graft thromboses. The effect of aspirin, dipyridamole and Lipo PGE1 plus low-dose heparin on any outcomes is unclear (very low certainty evidence). Two studies (168 participants) assessed interventions in liver transplants. One compared warfarin versus aspirin in patients with pre-existing portal vein thrombosis and the other investigated plasmapheresis plus anticoagulation. Both studies were abstract-only publications, had high risk of bias in several domains, and no outcomes could be meta-analysed. Overall, the effect of any of these interventions on any of our outcomes remains unclear with no evidence to guide anti-thrombotic therapy in standard liver transplant recipients (very low certainty evidence).

Authors' conclusions: Overall, there is a paucity of research in the field of graft thrombosis prevention. Due to a lack of high quality evidence, it remains unclear whether any therapy is able to reduce the rate of early graft thrombosis in any type of solid organ transplant. UFH may increase the risk of major bleeding in kidney transplant recipients, however this is based on low certainty evidence. There is no evidence from RCTs to guide anti-thrombotic strategies in liver, heart, lung, or other solid organ transplants. Further studies are required in comparing anticoagulants, antiplatelets to placebo in solid organ transplantation. These should focus on outcomes such as early graft thrombosis, major haemorrhagic complications, return to theatre, and patient/graft survival.

PubMed Disclaimer

Conflict of interest statement

  1. Vignesh Surianarayanan has declared that they have no conflict of interest

  2. Thomas J Hoather has declared that they have no conflict of interest

  3. Samuel J Tingle has declared that they have no conflict of interest

  4. Emily Thompson has declared that they have no conflict of interest

  5. John Hanley has declared that they have no conflict of interest

  6. Colin H Wilson has declared that they have no conflict of interest

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
1.1
1.1. Analysis
Comparison 1: Heparin versus placebo in kidney transplant recipients, Outcome 1: Major bleeding events: unfractionated heparin
1.2
1.2. Analysis
Comparison 1: Heparin versus placebo in kidney transplant recipients, Outcome 2: Major bleeding events: all heparin
1.3
1.3. Analysis
Comparison 1: Heparin versus placebo in kidney transplant recipients, Outcome 3: Readmissions to intensive care: all heparin
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Horvath 1975 {published data only}
    1. Horvath JS, Tiller DJ, Duggin GG, McGrath BP, Montenegro R, Johnson JR. Low dose heparin and early kidney transplant function. Australian & New Zealand Journal of Medicine 1975;5(6):537-9. [MEDLINE: ] - PubMed
Kauffman 1980 {published data only}
    1. Kauffman HM, Adams MB, Hebert LA, Walczak PM. Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings 1980;12(2):311-4. [MEDLINE: ] - PubMed
Kikic 2009 {published data only}
    1. Kikic Z, Lorenz M, Sunder-Plassmann G, Schillinger M, Regele H, Gyori G, et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation 2009;88(12):1377-85. [MEDLINE: ] - PubMed
    1. Kikic Z, Matthias L, Sunder-Plassmann G, Schillinger M, Regele H, Gyori G, et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International 2009;22(Suppl 2):184. [CENTRAL: CN-01912347] - PubMed
Mansourian 2014 {published data only}
    1. Mansourian M, Kazemi K, Nikeghbalian S, Shamsaefaar A, Shafiee M, Fakhar N, et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental & Clinical Transplantation 2014;12(Suppl 2):270. [EMBASE: 71976559]
Osman 2007 {published data only}
    1. Osman Y, Kamal M, Soliman S, Sheashaa H, Shokeir A, Shehab el-Dein AB. Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology 2007;69(4):647-51. [MEDLINE: ] - PubMed
Ubhi 1989 {published data only}
    1. Ubhi CS, Lam FT, Mavor AI, Giles GR. Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation 1989;48(5):886-7. [MEDLINE: 2815265] - PubMed
Villamil 2016 {published data only}
    1. Villamil A, Bandi JC, Nunez F, Mullen EG, Yamamoto L, De Santibanes E, et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology 2016;64(1 Suppl 1):494A. [EMBASE: 612594651]
Zhang 2005 {published data only}
    1. Zhang Y, Guan D, Xia C, Han Z, Xu J, Gao J, et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation 2004;4(Suppl 8):163. [CENTRAL: CN-00509578]
    1. Zhang Y, Guan DL, Xia CQ, Han ZY, Xu JJ, Gao JZ, et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings 2005;37(10):4208-10. [MEDLINE: ] - PubMed
Zhang 2009a {published data only}
    1. Zhang Y, Zhang XD, Ma LL, Guan DL. Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings 2009;41(5):1547-51. [MEDLINE: ] - PubMed

References to studies excluded from this review

Zhang 2003a {published data only}
    1. Zhang Y, Guan D, Xia C. The relationship between the peripheral blood of CD61, CD63, PAC-1 and the transplant kidney function [abstract]. In: XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL. 2002. [CENTRAL: CN-00417006]
    1. Zhang Y, Guan DL, Xia CQ, Han ZY, Xu JJ, Gao JZ, et al. Relationship between the expression levels of CD61, CD63, and PAC-1 on platelet surface in peripheral blood and the transplanted kidney function [Erratum in: Transplant Proc. 2003 Aug;35(5):2060 Note: Zhang YG [corrected to Zhang Y]; Guan D [corrected to Guan D L]]. Transplantation Proceedings 2003;35(4):1360-3. [MEDLINE: ] - PubMed
    1. Zhang Y, Guan DL, Xia CQ, Han ZY, Xu JJ, Gao JZ, et al. The relationship between the peripheral blood of CD61, CD63, PAC-1 and the transplant kidney function. Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery] 2003;41(12):881-4. [MEDLINE: ] - PubMed

Additional references

Alkhunaizi 1998
    1. Alkhunaizi AM, Olyaei AJ, Barry JM, deMattos AM, Conlin MJ, Lemmers MJ, et al. Efficacy and safety of low molecular weight heparin in renal transplantation. Transplantation 1998;66(4):533-4. [MEDLINE: 9734500 ] - PubMed
Bakir 1996
    1. Bakir N, Sluiter WJ, Ploeg RJ, Son WJ, Tegzess AM. Primary renal graft thrombosis. Nephrology Dialysis Transplantation 1996;11(1):140-7. [MEDLINE: ] - PubMed
Blundell 2020
    1. Blundell J, Shahrestani S, Lendzion R, Pleass HJ, Hawthorne WJ. Risk factors for early pancreatic allograft thrombosis following simultaneous pancreas-kidney transplantation: a systematic review. Clinical & Applied Thrombosis/Hemostasis 2020;26:1076029620942589. [MEDLINE: ] - PMC - PubMed
Cherian 2010
    1. Cherian TP, Chiu K, Gunson B, Bramhall SR, Mayer D, Mirza DF, et al. Pulmonary thromboembolism in liver transplantation: a retrospective review of the first 25 years. Transplant International 2010;23(11):1113-9. [MEDLINE: ] - PubMed
Costanzo 2010
    1. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. Journal of Heart & Lung Transplantation 2010;29(8):914-56. [MEDLINE: ] - PubMed
Friedman 2001
    1. Friedman GS, Meier-Kriesche HU, Kaplan B, Mathis AS, Bonomini L, Shah N, et al. Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation 2001;72(6):1073-8. [MEDLINE: 11579303] - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10. [MEDLINE: ] - PubMed
Gilabert 2002
    1. Gilabert R, Fernandez-Cruz L, Real MI, Ricart MJ, Astudillo E, Montana X. Treatment and outcome of pancreatic venous graft thrombosis after kidney-pancreas transplantation. British Journal of Surgery 2002;89(3):355-60. [MEDLINE: ] - PubMed
GRADE 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: ] - PMC - PubMed
GRADE 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [MEDLINE: ] - PubMed
Gruessner 1996
    1. Gruessner A, Sutherland DE. Pancreas transplantation in the United States (US) and non-US as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Clinical Transplants 1996:47-67. [MEDLINE: ] - PubMed
Gruessner 1997
    1. Gruessner RW, Sutherland DE, Troppmann C, Benedetti E, Hakim N, Dunn DL, et al. The surgical risk of pancreas transplantation in the cyclosporine era: an overview. Journal of the American College of Surgeons 1997;185(2):128-44. [MEDLINE: ] - PubMed
Hamed 2015
    1. Hamed MO, Chen Y, Pasea L, Watson PJ, Torpey N, Bradley JA, et al. Early graft loss after kidney transplantation: risk factors and consequences. American Journal of Transplantation 2015;15(6):1632-43. [MEDLINE: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: ] - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Innes 2021
    1. Innes A, Tingle S, Ibrahim I, Thompson E, Bates L, Manas D, White S, Wilson C. Use of Dextran 40 After Pancreas Transplant May Reduce Early Inflammation and Significant Bleeding Compared to a Heparin-Based Protocol. Transplantation proceedings March 2021;53(2):712-715. - PubMed
Irish 2004
    1. Irish A. Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. American Journal of Cardiovascular Drugs 2004;4(3):139-49. [MEDLINE: ] - PubMed
Kahan 2007
    1. Kahan ES, Petersen G, Gaughan JP, Criner GJ. High incidence of venous thromboembolic events in lung transplant recipients. Journal of Heart & Lung Transplantation 2007;26(4):339-44. [MEDLINE: ] - PubMed
Kaur 2009
    1. Kaur J, Jones N, Mallett S. Thrombelastography platelet mapping is a useful preoperative tool in surgical patients taking antiplatelet medication. British Journal of Anaesthesia 2009;103(2):304; author reply 304-5. [MEDLINE: ] - PubMed
Kopp 2018
    1. Kopp WH, Leeuwen CAT, Lam DH, Huurman VAL, Fijter JW, Schaapherder AF, et al. Retrospective study on detection, treatment, and clinical outcome of graft thrombosis following pancreas transplantation. Transplant International 2018;32(4):410-7. [MEDLINE: ] - PMC - PubMed
Kroshus 1995
    1. Kroshus TJ, Kshettry VR, Hertz MI, Morton Bolman RM 3rd. Deep venous thrombosis and pulmonary embolism after lung transplantation. Journal of Thoracic & Cardiovascular Surgery 1995;110(2):540-4. [MEDLINE: ] - PubMed
Leibowitz 1994
    1. Leibowitz DW, Smith CR, Michler RE, Ginsburg M, Schulman LL, McGregor CC, et al. Incidence of pulmonary vein complications after lung transplantation: a prospective transesophageal echocardiographic study. Journal of the American College of Cardiology 1994;24(3):671-5. [MEDLINE: ] - PubMed
Mourad 2014
    1. Mourad MM, Liosis C, Gunson BK, Mergental H, Isaac J, Muiesan P, et al. Aetiology and management of hepatic artery thrombosis after adult liver transplantation. Liver Transplantation 2014;20(6):713-23. [DOI: 10.1002/lt.23874] - DOI - PubMed
Mullins 1992
    1. Mullins PA, Cary NR, Sharples L, Scott J, Aravot D, Large SR, et al. Coronary occlusive disease and late graft failure after cardiac transplantation. British Heart Journal 1992;68(3):260-5. [MEDLINE: ] - PMC - PubMed
Muthusamy 2010
    1. Muthusamy AS, Giangrande PL, Friend PJ. Pancreas allograft thrombosis. Transplantation 2010;90(7):705-7. [MEDLINE: ] - PubMed
Osman 2003
    1. Osman Y, Shokeir A, Ali-el-Dein B, Tantawy M, Wafa EW, el-Dein AB, et al. Vascular complications after live donor renal transplantation: study of risk factors and effects on graft and patient survival. Journal of Urology 2003;169(3):859-62. [MEDLINE: ] - PubMed
Poli 2006
    1. Poli D, Zanazzi M, Antonucci E, Bertoni E, Salvadori M, Abbate R, et al. Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis. Journal of Thrombosis & Haemostasis 2006;4(5):988-92. [MEDLINE: ] - PubMed
Sáez‐Giménez 2014
    1. Sáez-Giménez B, Berastegui C, Loor K, López-Meseguer M, Monforte V, Bravo C, et al. Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem. Transplantation Reviews 2014;29(2):85-92. [MEDLINE: 25573688 ] - PubMed
Schunemann 2011a
    1. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Schunemann 2011b
    1. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Sugi 2017
    1. Sugi MD, Albadawi H, Knuttinen G, Naidu SG, Mathur AK, Moss AA, et al. Transplant artery thrombosis and outcomes. Cardiovascular Diagnosis & Therapy 2017;7(Suppl 3):S219-27. [MEDLINE: ] - PMC - PubMed
Troppmann 1998
    1. Troppmann C, Gruessner AC, Dunn DL, Sutherland DE, Gruessner RW. Surgical complications requiring early relaparotomy after pancreas transplantation: a multivariate risk factor and economic impact analysis of the cyclosporine era. Annals of Surgery 1998;227(2):255-68. [MEDLINE: ] - PMC - PubMed
Wozney 1986
    1. Wozney P, Zajko AB, Bron KM, Point S, Starzl TE. Vascular complications after liver transplantation: a 5-year experience. AJR. American Journal of Roentgenology 1986;147(4):657-63. [MEDLINE: ] - PMC - PubMed

References to other published versions of this review

Kilner 2015
    1. Kilner M, Hanley J, Biss TT, Talks K, Wilson CH. Interventions for preventing thrombosis in solid organ transplant recipients. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD011557. DOI: 10.1002/14651858.CD011557. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No: CD011557. [DOI: 10.1002/14651858.CD011557] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources